Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712282 | 1.00 | HDAC6 (0.55) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL27152631 | 0.88 | RARB (0.48) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL19384961 | 0.88 | HDAC1 (0.65) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL29712264 | 0.88 | HDAC1 (0.65) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL18205159 | 0.85 | HDAC4 (0.52) | HDAC6HDAC8HDAC4 | |
| SCHEMBL28506632 | 0.84 | HDAC1 (0.51) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL21125023 | 0.84 | HDAC6 (0.53) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL21330353 | 0.83 | HDAC4 (0.69) | HDAC6HDAC1HDAC5HDAC8HDAC4 | |
| SCHEMBL19384927 | 0.82 | HDAC1 (0.51) | HDAC6HDAC1HDAC5HDAC8 | |
| SCHEMBL25312552 | 0.81 | HDAC6 (0.52) | HDAC6HDAC1HDAC5HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291810-B1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-109071520-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11192867-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| CN-107735088-B | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-3433252-B1 | MICROBICIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-107735087-B | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-11083196-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-08-10 | — | — | US | disclosed |
| EP-3464251-B1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| WO-2017207757-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017162868-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-28 | — | — | WO | disclosed |
| US-20160333001-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333001-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2016179554-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016179550-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016179550-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016179554-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083196-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | HDAC6 610/4885HDAC1 551/4885HDAC5 1156/4885 |
| US-11192867-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | HDAC6 611/4885HDAC1 584/4885HDAC5 1226/4885 |
| US-20160333001-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC6 9/4885HDAC1 1/4885HDAC5 3/4885 |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | HDAC6 610/4885HDAC1 551/4885HDAC5 1156/4885 |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC6 9/4885HDAC1 1/4885HDAC5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.